References: 1. Sims EK, Carr ALJ, Oram RA, et al. 100 years of insulin: celebrating the past, present and future of diabetes therapy.
Nat Med. 2021;27(7):1154-1164.
2. Thakkar S, Chopra A, Nagendra L, et al. Teplizumab in type 1 diabetes mellitus: an updated review.
touchREV Endocrinol. 2023;19(2):22-30.
3. diaTribe Learn. FDA approves Tzield (teplizumab) to delay type 1 diabetes. Published November 17, 2022. Updated November 21, 2022.
https://diatribe.org/diabetes-medications/fda-approves-tzield-teplizumab-delay-type-1-diabetes4. Pham-Huy A, Top KA, Constantinescu C, et al. The use and impact of monoclonal antibody biologics during pregnancy.
CMAJ. 2021;193(29):1129-1136.
5. American Diabetes Association Diabetes Dialogues. Insulin is now a biologic—what does that mean? Accessed April 15, 2024.
https://diabetes.org/blog/insulin-now-biologic-what-does-mean 6. TZIELD Prescribing Information. Provention Bio, Inc; 2023.
7. Insel RA, Dunne JL, Atkinson MA, et al. Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.
Diabetes Care. 2015;38(10):1964-1974.
8. American Diabetes Association Professional Practice Committee. Diagnosis and classification of diabetes: standards of care in diabetes—2024.
Diabetes Care. 2024;47(Suppl 1): S20–S42.
9. Type 1 Diabetes TrialNet. Protocol TN-10. Version June 2014. Accessed May 5, 2023.
https://classic.clinicaltrials.gov/ProvidedDocs/61/NCT01030861/Prot_000.pdf 10. Edelman S. Early intervention by family physicians to delay type 1 diabetes.
J Fam Pract. 2023:72(6 suppl):S19-S24.